Journal
SYNLETT
Volume 27, Issue 13, Pages 1898-1906Publisher
GEORG THIEME VERLAG KG
DOI: 10.1055/s-0035-1561465
Keywords
total synthesis; cyclic peptide; cancer; tumor hypoxia; natural products
Categories
Funding
- Lundbeck foundation
- Danish Cancer Society
- Carlsberg foundation
- Ministry of Higher Education and Science [AU-2010-612-181]
- Lundbeck Foundation [R105-2011-9308] Funding Source: researchfish
Ask authors/readers for more resources
Rakicidin A is a prominent member of a small class of macrocyclic lipodepsipeptide natural products that contain an electrophilic 4-amido-2,4-pentadienoate (APD) functionality. Rakicidin A displays selective growth inhibitory activity against hypoxic cancer cells as well as imatinib-resistant chronic myelogenous leukemia (CML) cells. In this paper we present and discuss the two known synthetic routes to rakicidin A, which provide an instructive comparison of strategies used to address the synthetic challenges inherent to rakicidin A. In addition to the synthetic discussion we provide a status on the ongoing biological investigations and emerging structure-activity relationships of the rakicidin scaffold. 1 Introduction 2 The APD-CLD Class of Natural Products 3 Total Syntheses of Rakicidin A 4 Biological Investigations of Rakicidin A and Analogues 5 Conclusion and Perspectives
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available